Table 3 Immunophenotype and molecular analysis of biopsies from 19 patients with HV-LPD
Case | CD3 | CD8 | CD4 | CD56 | TIA1 | CD30 | Ki67 | EBERs | TCR rearrangement |
|---|---|---|---|---|---|---|---|---|---|
1 | + | + | – | – | + | – | 30% | + | – |
2 | + | – | – | + | + | – | 60% | + | – |
3 | + | – | – | + | + | – | 30% | + | ND |
4 | + | – | + | – | + | P+ | 80% | + | – |
5 | + | + | – | – | + | ND | 30% | + | – |
6 | + | – | – | + | + | ND | 30% | + | – |
7 | + | + | – | – | + | – | 30% | + | – |
8 | + | – | – | + | + | P+ | 50% | + | ND |
9 | + | – | + | – | + | + | 70% | + | + |
10 | + | + | – | – | + | ND | 20% | + | + |
11 | + | + | – | – | + | – | 30% | + | + |
12 | + | – | – | + | + | – | 30% | + | ND |
13 | + | – | – | + | + | + | 70% | + | F |
14 | + | – | + | – | + | ND | 40% | + | + |
15 | + | – | – | + | + | – | 60% | + | – |
16 | + | – | + | – | + | P+ | 70% | + | + |
17 | + | – | + | – | + | + | 40% | + | + |
18 | + | – | + | – | + | – | 10% | + | + |
19 | + | – | + | – | + | – | 60% | + | – |